From January 1, 2023 to March 31, 2023, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 988,501 shares, representing 0.13% for CNY 18.93 million under the buyback announced on September 1, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.41 CNY | -2.00% | -8.02% | +0.62% |
09/05 | Pacific Shuanglin Bio-pharmacy Subsidiary Gets Plasmapheresis License | MT |
26/04 | Pacific Shuanglin Bio-pharmacy Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+0.62% | 2.83B | |
+0.10% | 91.42B | |
+3.16% | 41.08B | |
-10.99% | 34.26B | |
+53.99% | 25.27B | |
-10.07% | 12.81B | |
-12.25% | 11.6B | |
-44.00% | 11.42B | |
+5.77% | 9.16B | |
-6.90% | 8.22B |
- Stock Market
- Equities
- 000403 Stock
- News Pacific Shuanglin Bio-pharmacy Co., LTD
- Tranche Update on Pacific Shuanglin Bio-pharmacy Co., LTD's Equity Buyback Plan announced on September 1, 2022.